Postes actifs de Claude Perreault
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
SpecificiT Pharma, Inc.
 SpecificiT Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SpecificiT Pharma, Inc. develops personalized cancer immunotherapies. The company is headquartered in Westmount, Canada. | Fondateur | - | - |
Historique de carrière de Claude Perreault
Anciens postes connus de Claude Perreault
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Epitopea Ltd.
 Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Fondateur | 01/01/2021 | - |
Statistiques
Internationale
| Canada | 2 |
| Royaume-Uni | 2 |
Opérationnelle
| Founder | 2 |
Sectorielle
| Commercial Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
SpecificiT Pharma, Inc.
SpecificiT Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SpecificiT Pharma, Inc. develops personalized cancer immunotherapies. The company is headquartered in Westmount, Canada. | Commercial Services |
Epitopea Ltd.
Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Commercial Services |
- Bourse
- Insiders
- Claude Perreault
- Expérience
